AngioDynamics Q3 2024 Earnings Report $8.89 +0.31 (+3.61%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast AngioDynamics EPS ResultsActual EPS-$0.16Consensus EPS -$0.14Beat/MissMissed by -$0.02One Year Ago EPSN/AAngioDynamics Revenue ResultsActual Revenue$75.18 millionExpected Revenue$76.71 millionBeat/MissMissed by -$1.53 millionYoY Revenue GrowthN/AAngioDynamics Announcement DetailsQuarterQ3 2024Date4/4/2024TimeN/AConference Call ResourcesSlide DeckPress ReleaseANGO Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Missed Nvidia? Buy Elon Musk’s “Silent Partner” (Ad)In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.So please click here to see the details because a lot of people could get rich. AngioDynamics Earnings HeadlinesAngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor EventDecember 19 at 5:00 PM | businesswire.comContrasting AngioDynamics (NASDAQ:ANGO) & West Pharmaceutical Services (NYSE:WST)December 17, 2024 | americanbankingnews.comI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. December 22, 2024 | Porter & Company (Ad)AngioDynamics Receives FDA Clearance for NanoKnife System, Poised for Growth with New Market Opportunities and Clinical SuccessDecember 11, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Protagonist Therapeutics (PTGX)December 10, 2024 | markets.businessinsider.comNanoKnife gains FDA clearance for prostate tissue ablationDecember 9, 2024 | finance.yahoo.comSee More AngioDynamics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AngioDynamics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AngioDynamics and other key companies, straight to your email. Email Address About AngioDynamicsAngioDynamics (NASDAQ:ANGO), a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.View AngioDynamics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
